Real-world effectiveness of dupilumab in COPD: a German multicenter analysis

Abstract Background Dupilumab reduced exacerbations in patients with COPD and type 2 inflammation in clinical trials; however, multicenter real-world data remain limited. Methods We performed a multicenter analysis of patients with COPD treated with dupilumab across centers in Germany. Patients with comorbid asthma were included to compare outcomes between COPD-only patients and those with comorbid asthma, as well as between patients with and without chronic bronchitis (CB). The primary endpoint was change in the annualized rate of moderate-to-severe exacerbations. Changes in lung function and CAT score were also assessed. Results A total of 99 patients were included (60% male, mean age 66 years, FEV₁ 37% predicted, DLCO 41% predicted, 45% comorbid asthma, 58% CB, 7% current smokers). Over a median follow-up of 11 months [IQR 8–14], dupilumab reduced the annualized moderate-to-severe exacerbation rate from 3.52 (95% CI 2.94–4.09) at baseline to 1.04 (95% CI 0.71–1.37) during follow-up, corresponding to a 70% reduction. Reductions in exacerbation rates were consistent irrespective of exacerbation severity, comorbid asthma, CB, or emphysema severity. CAT improved by a mean of 4.5 points. FEV₁ improved by 50 mL ( p = 0.077), while greater improvements were observed for residual volume (− 150 mL; p = 0.071) and total airway resistance (− 12.6%; p < 0.001). Eight patients were non-responders and had no reduction in exacerbation under treatment. Conclusion In this real-world multicenter cohort, dupilumab effectively reduced exacerbation burden in patients with COPD and type 2 inflammation. Exploratory subgroup analyses suggested consistent treatment effects across different clinical phenotypes, although these findings require confirmation in larger studies. The high baseline exacerbation burden may partly explain the marked treatment response.

Authors

Institutions

Publication Details

Journal
Respiratory Research
Published
2026-10-06
DOI
https://doi.org/10.1186/s12931-026-03940-8
Primary Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world effectiveness of dupilumab in COPD: a German multicenter analysis

Vera Veith, Daiana Stolz, Ralf‐Harto Hübner, Maria Aetou et al.
Respiratory Research
Chronic Obstructive Pulmonary Disease (COPD) Research
article

Real-world effectiveness of dupilumab in COPD: a German multicenter analysis

Vera Veith, Daiana Stolz, Ralf‐Harto Hübner, Maria Aetou, Nora Drick, K. Milger, Marek Lommatzsch, Frederik Trinkmann, Peter J. Alter, Jan Heyckendorf, Konstantina Kontogianni, Eva Pappe, Benjamin Waschki, Kathrin Kahnert, Leonie Biener, Timm Greulich, Pontus Mertsch, Mustafa Abdo, Jeremias Götschke, Henrik Watz, Jessica Rademacher, Michael Dreher, Dirk Skowasch, Claus Neurohr, Sebastian Sander
article en

Abstract

Abstract Background Dupilumab reduced exacerbations in patients with COPD and type 2 inflammation in clinical trials; however, multicenter real-world data remain limited. Methods We performed a multicenter analysis of patients with COPD treated with dupilumab across centers in Germany. Patients with comorbid asthma were included to compare outcomes between COPD-only patients and those with comorbid asthma, as well as between patients with and without chronic bronchitis (CB). The primary endpoint was change in the annualized rate of moderate-to-severe exacerbations. Changes in lung function and CAT score were also assessed. Results A total of 99 patients were included (60% male, mean age 66 years, FEV₁ 37% predicted, DLCO 41% predicted, 45% comorbid asthma, 58% CB, 7% current smokers). Over a median follow-up of 11 months [IQR 8–14], dupilumab reduced the annualized moderate-to-severe exacerbation rate from 3.52 (95% CI 2.94–4.09) at baseline to 1.04 (95% CI 0.71–1.37) during follow-up, corresponding to a 70% reduction. Reductions in exacerbation rates were consistent irrespective of exacerbation severity, comorbid asthma, CB, or emphysema severity. CAT improved by a mean of 4.5 points. FEV₁ improved by 50 mL ( p = 0.077), while greater improvements were observed for residual volume (− 150 mL; p = 0.071) and total airway resistance (− 12.6%; p < 0.001). Eight patients were non-responders and had no reduction in exacerbation under treatment. Conclusion In this real-world multicenter cohort, dupilumab effectively reduced exacerbation burden in patients with COPD and type 2 inflammation. Exploratory subgroup analyses suggested consistent treatment effects across different clinical phenotypes, although these findings require confirmation in larger studies. The high baseline exacerbation burden may partly explain the marked treatment response.

Respiratory Research
University of Freiburg (DE), Philipps University of Marburg (DE), Medical University of Graz (AT), Heidelberg University (DE), Universitätsklinikum Gießen und Marburg (DE), University Hospital Bonn (DE), Medizinische Hochschule Hannover (DE), Humboldt-Universität zu Berlin (DE), University Hospital Schleswig-Holstein (DE), Universitätsklinikum Aachen (DE), German Center for Lung Research (DE), LungenClinic Grosshansdorf (DE), University of Rostock (DE), Ludwig-Maximilians-Universität München (DE), University of Lübeck (DE)
Openalex Percentile: Top 11%
Chronic Obstructive Pulmonary Disease (COPD) Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.